Sign In
Buy MLTX
$19.02
-0.340 (-1.76%)
At Close: Jul 24, 2026
NEW YORK , Nov. 18, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in MoonLake Immunotherapeutics ("MoonLake" or the "Company") (NASDAQ: MLTX) of a class action securities lawsuit. CLAS
MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – MLTX
08:50am, Tuesday, 18'th Nov 2025
LOS ANGELES, Nov. 18, 2025 (GLOBE NEWSWIRE) -- The DJS Law Group reminds investors of a class action lawsuit against MoonLake Immunotherapeutics (“MoonLake” or “the Company”) (NASDAQ: MLTX) fo
SAN DIEGO, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that the MoonLake class action lawsuit – captioned Peters v. MoonLake Immunotherapeutics, No. 25-cv-08612 (S.D
MoonLake: Ignore The Panic, Catch The Upside
12:33am, Tuesday, 18'th Nov 2025
MoonLake Immunotherapeutics is rated Buy, with sonelokimab having multiple dermatology and rheumatology indications. MLTX's VELA-1 trial succeeded, and VELA-2's statistical miss was due to elevated pl
MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit
09:45pm, Monday, 17'th Nov 2025
NEW YORK , Nov. 17, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 202
New York, New York--(Newsfile Corp. - November 17, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) bet
New York, New York--(Newsfile Corp. - November 17, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against MoonLake Immunotherapeutics (NASDAQ: M
SAN FRANCISCO, Nov. 17, 2025 (GLOBE NEWSWIRE) -- A securities class action, styled Bridgewood v. MoonLake Immunotherapeutics, et al., No. 1:25-cv-08500 (S.D.N.Y), has been filed after MoonLake (NASDAQ
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics
12:47pm, Monday, 17'th Nov 2025
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In MoonLake To Contact Him Directly To Discuss Their Options If you purchased or acquire
MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit with the Schall Law Firm
11:30am, Monday, 17'th Nov 2025
LOS ANGELES, Nov. 17, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against MoonLake Immunotherapeutics (“
PHILADELPHIA , Nov. 17, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against MoonLake Immunotherapeutics (NASDAQ: MLTX) ("MoonLake" or the "
NEW YORK , Nov. 17, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of MoonLake Immunotherapeutics (NASDAQ: MLTX). Shareholders who purchased shares of MLTX during
MoonLake Immunotherapeutics (MLTX) Class Action Lawsuit: Levi & Korsinsky Reminds Investors of December 15, 2025 Deadline
08:38am, Monday, 17'th Nov 2025
New York, New York--(Newsfile Corp. - November 17, 2025) - If you suffered a loss on your MoonLake Immunotherapeutics (NASDAQ: MLTX) investment and want to learn about a potential recovery under the f
MoonLake Immunotherapeutics investors that lost money are notified to contact BFA before the December 15, 2025 securities fraud class action deadline.
NEW YORK, Nov. 16, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2
